Activated Charcoal
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Activated Charcoal
- Activated Charcoal: From Gastrointestinal Adsorbent Use to Jeune Syndrome Situs Inversus
Activated Charcoal: From Gastrointestinal Adsorbent Use to Jeune Syndrome Situs Inversus
One-Sentence Summary
Activated charcoal is a non-absorbed oral adsorbent. It is marketed in Singapore as single-ingredient capsules and tablets, but none of the three registrations lists an approved indication. The TxGNN model predicts it may be effective for Jeune syndrome situs inversus, but there are 0 clinical trials and 0 publications for this disease, so the prediction rests on the model alone and has no clinical support.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration records |
| Predicted New Indication | Jeune syndrome situs inversus |
| TxGNN Prediction Score | 89.94% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, activated charcoal is a non-absorbed gastrointestinal adsorbent. It binds substances in the gut and limits their absorption, which is why it is used for overdose and poisoning decontamination.
Jeune syndrome is a genetic ciliopathy with skeletal and thoracic abnormalities. There is no plausible mechanistic link between the two conditions. The high TxGNN score looks like an artifact of the network-based prediction rather than a clinically meaningful signal.
The other top-ranked predictions show the same pattern. Most are congenital or chromosomal conditions (orofacial clefting syndrome, Pierre Robin syndrome variants, chromosome 22q and 7q partial deletions, Laubry-Pezzi syndrome) with no trials, no literature and no mechanistic rationale. Two have some literature, but it does not support a treatment role:
- Heart disease: the articles describe charcoal as GI decontamination in cardiotoxic overdoses (calcium channel blockers, beta-blockers, cardiac glycosides, tricyclic antidepressants). Charcoal limits absorption of the toxic drug and does not treat heart disease itself.
- Disorder of fucoglycosan synthesis: the articles cover overdose, uremic toxin adsorption in chronic kidney disease and pharmacokinetics. None addresses glycosylation disorders.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the top-ranked predicted indication, Jeune syndrome situs inversus.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05799P | NORIT CAPSULE 200 mg | Capsule | Not stated |
| SIN10625P | CHARCOAL TABLET 200 mg | Tablet | Not stated |
| SIN06063P | NORIT TABLET 125 mg | Tablet | Not stated |
All three are valid, single-ingredient oral products.
Safety Considerations
- Drug Interactions: 76 interactions were recorded. Most of those reviewed are rated Moderate, with Acetylcysteine rated Minor. Charcoal can adsorb co-administered oral drugs and reduce their absorption. Examples include:
- Analgesics: acetaminophen, acetylsalicylic acid, choline salicylate
- Tetracycline antibiotics: doxycycline, minocycline, tetracycline
- Tricyclic antidepressants: amitriptyline, clomipramine, desipramine, doxepin
- Others: digoxin, carbamazepine, valproic acid, theophylline, dyphylline, acarbose, chlorpropamide, amobarbital, prochlorperazine
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or disease-specific literature (Evidence Level L5), and there is no plausible mechanistic link between a non-absorbed GI adsorbent and a genetic ciliopathy. The other nine top-ranked predictions are equally unsupported.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, since safety screening cannot proceed without them
- Mechanism of action data from DrugBank
- Approved indication text for the Singapore registrations
- Any direct preclinical or clinical evidence linking activated charcoal to the predicted disease. Without it, further investment is not recommended.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.